Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer

Biomaterials

Volumn 116, Issue , 2017, Pages 82-94

  Zhao, Kaidong ^a,b,c   Li, Di ^b   Xu, Weiguo ^b   Ding, Jianxun ^b   Jiang, Weiqian ^d   Li, Mingqiang ^b   Wang, Chunxi ^a   Chen, Xuesi ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^c Benxi Beiying Iron and Steel Group Co Ltd   (China)

^d Department of Earth and Environmental Sciences   (United States)

Author keywords

Chemotherapy; Hydroxyethyl starch prodrug; Prostate cancer therapy; Schiff base bond; Targeted drug delivery

Indexed keywords

CHEMOTHERAPY; MAMMALS; PATHOLOGY; STARCH; UROLOGY;

ANTI-PROLIFERATIVE; AQUEOUS ENVIRONMENT; HYDROXYETHYL STARCHES; PRODRUGS; PROSTATE CANCERS; SCHIFF-BASE; SYSTEMIC TOXICITIES; TARGETED DRUG DELIVERY;

DISEASES;

DOXORUBICIN; GONADORELIN; HETASTARCH; PRODRUG; SCHIFF BASE; HETASTARCH DERIVATIVE; NANOCAPSULE; NANOCONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; MICELLE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; TREATMENT OUTCOME;

ANIMALS; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; GONADOTROPIN-RELEASING HORMONE; HYDROGEN-ION CONCENTRATION; HYDROXYETHYL STARCH DERIVATIVES; MALE; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NANOCONJUGATES; NEOPLASM METASTASIS; PRODRUGS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84999836154     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.11.030     Document Type: Article

References (56)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66:1 (2016), 7–30.
2. [2] Amanee, D.S., Patrick, T.J.H., Aliza, P., Hadiyah, N.G., Ho-wook, J., Derrick, D., Nanodiamonds enhance therapeutic efficacy of doxorubicin in treating metastatic hormone-refractory prostate cancer. Nanotechnology, 25(42), 2014, 425103.
3. [3] Fahrenholtz, C.D., Rick, F.G., Garcia, M.I., Zarandi, M., Cai, R.Z., Block, N.L., Schally, A.V., Burnstein, K.L., Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 111:3 (2014), 1084–1089.
4. [4] Tennakoon, J.B., Shi, Y., Han, J.J., Tsouko, E., White, M.A., Burns, A.R., Zhang, A., Xia, X., Ilkayeva, O.R., Xin, L., Ittmann, M.M., Rick, F.G., Schally, A.V., Frigo, D.E., Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene 33:45 (2014), 5251–5261.
5. [5] Popovics, P., Schally, A.V., Szalontay, L., Block, N.L., Rick, F.G., Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget 5:12 (2014), 4567–4578.
6. [6] Liu, S.V., Liu, S., Pinski, J., Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin. Invest. Drugs 20:6 (2011), 769–778.
7. [7] Heidenreich, A., Pfister, D., Merseburger, A., Bartsch, G., German working group on castration-resistant prostate, castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know. Eur. Urol. 64:2 (2013), 260–265.
8. [8] Liu, S.V., Schally, A.V., Hawes, D., Xiong, S., Fazli, L., Gleave, M., Cai, J., Groshen, S., Brands, F., Engel, J., Pinski, J., Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin. Cancer Res. 16:18 (2010), 4675–4680.
9. [9] Huang, K., Shi, B., Xu, W., Ding, J., Yang, Y., Liu, H., Zhuang, X., Chen, X., Reduction-responsive polypeptide nanogel delivers antitumor drug for improved efficacy and safety. Acta Biomater. 27 (2015), 179–193.
10. [10] Ding, J., Shi, F., Li, D., Chen, L., Zhuang, X., Chen, X., Enhanced endocytosis of acid-sensitive doxorubicin derivatives with intelligent nanogel for improved security and efficacy. Biomater. Sci. 1:6 (2013), 633–646.
11. [11] Petrioli, R., Fiaschi, A.I., Francini, E., Pascucci, A., Francini, G., The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat. Rev. 34:8 (2008), 710–718.
12. [12] Xu, W., Ding, J., Xiao, C., Li, L., Zhuang, X., Chen, X., Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. Biomaterials 54 (2015), 72–86.
13. [13] Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., Moens, A.L., Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 52:6 (2012), 1213–1225.
14. [14] Kopeček, J., Polymer–drug conjugates: Origins, progress to date and future directions. Adv. Drug Deliv. Rev. 65:1 (2013), 49–59.
15. [15] Larson, N., Ghandehari, H., Polymeric conjugates for drug delivery. Chem. Mater. 24:5 (2012), 840–853.
16. [16] Delplace, V., Couvreur, P., Nicolas, J., Recent trends in the design of anticancer polymer prodrug nanocarriers. Polym. Chem. 5:5 (2014), 1529–1544.
17. [17] Du, J.Z., Du, X.J., Mao, C.Q., Wang, J., Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 133:44 (2011), 17560–17563.
18. [18] Sun, D., Ding, J., Xiao, C., Chen, J., Zhuang, X., Chen, X., Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin. ACS Appl. Mater. Interfaces 6:23 (2014), 21202–21214.
19. [19] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
20. [20] Zhou, K., Wang, Y., Huang, X., Luby-Phelps, K., Sumer, B.D., Gao, J., Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew. Chem. Int. Ed. 50:27 (2011), 6109–6114.
21. [21] Iyer, A.K., Singh, A., Ganta, S., Amiji, M.M., Role of integrated cancer nanomedicine in overcoming drug resistance. Adv. Drug Deliv. Rev. 65:13–14 (2013), 1784–1802.
22. [22] Limonta, P., Marelli, M.M., Mai, S., Motta, M., Martini, L., Moretti, R.M., GnRH Receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr. Rev. 33:5 (2012), 784–811.
23. [23] Yu, S., Ding, J., He, C., Cao, Y., Xu, W., Chen, X., Disulfide cross-linked polyurethane micelles as a reduction-triggered drug delivery system for cancer therapy. Adv. Healthcare Mater. 3:5 (2014), 752–760.
24. [24] Dharap, S.S., Wang, Y., Chandna, P., Khandare, J.J., Qiu, B., Gunaseelan, S., Sinko, P.J., Stein, S., Farmanfarmaian, A., Minko, T., Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U. S. A. 102:36 (2005), 12962–12967.
25. [25] Baier, G., Baumann, D., Siebert, J.M., Musyanovych, A., Mailander, V., Landfester, K., Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. Biomacromolecules 13:9 (2012), 2704–2715.
26. [26] Li, D., Ding, J., Zhuang, X., Chen, L., Chen, X., Drug binding rate regulates the properties of polysaccharide prodrugs. J. Mater. Chem. B 4:30 (2016), 5167–5177.
27. [27] Noga, M., Edinger, D., Rödl, W., Wagner, E., Winter, G., Besheer, A., Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase. J. Control. Release 159:1 (2012), 92–103.
28. [28] Sagnella, S.M., Duong, H., MacMillan, A., Boyer, C., Whan, R., McCarroll, J.A., Davis, T.P., Kavallaris, M., Dextran-based doxorubicin nanocarriers with improved tumor penetration. Biomacromolecules 15:1 (2014), 262–275.
29. [29] Li, M., Tang, Z., Lv, S., Song, W., Hong, H., Jing, X., Zhang, Y., Chen, X., Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials 35:12 (2014), 3851–3864.
30. [30] Lin, C.J., Kuan, C.H., Wang, L.W., Wu, H.C., Chen, Y., Chang, C.W., Huang, R.Y., Wang, T.W., Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics. Biomaterials 90 (2016), 12–26.
31. [31] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:12 Part 1 (1986), 6387–6392.
32. [32] Ding, J., Xiao, C., Li, Y., Cheng, Y., Wang, N., He, C., Zhuang, X., Zhu, X., Chen, X., Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions. J. Control. Release 169:3 (2013), 193–203.
33. [33] Chen, G., Wang, L., Cordie, T., Vokoun, C., Eliceiri, K.W., Gong, S., Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials 47 (2015), 41–50.
34. [34] Brinkman, A.M., Chen, G., Wang, Y., Hedman, C.J., Sherer, N.M., Havighurst, T.C., Gong, S., Xu, W., Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 101 (2016), 20–31.
35. [35] Zhang, A., Zhang, Z., Shi, F., Xiao, C., Ding, J., Zhuang, X., He, C., Chen, L., Chen, X., Redox-sensitive shell-crosslinked polypeptide-block-polysaccharide micelles for efficient intracellular anticancer drug delivery. Macromol. Biosci. 13:9 (2013), 1249–1258.
36. [36] Bakaic, E., Smeets, N.M.B., Hoare, T., Injectable hydrogels based on poly(ethylene glycol) and derivatives as functional biomaterials. RSC Adv. 5:45 (2015), 35469–35486.
37. [37] Ding, J., Chen, J., Li, D., Xiao, C., Zhang, J., He, C., Zhuang, X., Chen, X., Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro. J. Mater. Chem. B 1:1 (2013), 69–81.
38. [38] Li, M., Tang, Z., Zhang, Y., Lv, S., Li, Q., Chen, X., Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 18 (2015), 132–143.
39. [39] Liu, X., Wang, J., Xu, W., Ding, J., Shi, B., Huang, K., Zhuang, X., Chen, X., Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model. Int. J. Nanomed. 10 (2015), 6587–6602.
40. [40] Zhang, Q., Ding, J., Lv, C., Xu, W., Sun, X., Meng, X., Epirubicin-complexed polypeptide micelle effectively and safely treats hepatocellular carcinoma. Polymers 7:11 (2015), 2410–2430.
41. [41] Yamaoka, T., Tabata, Y., Ikada, Y., Body distribution profile of polysaccharides after intravenous administration. Drug Deliv. 1:1 (1993), 75–82.
42. [42] Voeks, D.J., Martiniello-Wilks, R., Russell, P.J., Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urol. Oncol. 7:3 (2002), 111–118.
43. [43] Wang, J., Sun, X., Mao, W., Sun, W., Tang, J., Sui, M., Shen, Y., Gu, Z., Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv. Mater. 25:27 (2013), 3670–3676.
44. [44] Li, M., Tang, Z., Lin, J., Zhang, Y., Lv, S., Song, W., Huang, Y., Chen, X., Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer. Adv. Healthcare Mater. 3:11 (2014), 1877–1888.
45. [45] Bressenot, A., Marchal, S., Bezdetnaya, L., Garrier, J., Guillemin, F., Plenat, F., Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J. Histochem. Cytochem. 57:4 (2008), 289–300.
46. [46] Zhang, Y., Kim, W.Y., Huang, L., Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 34:13 (2013), 3447–3458.
47. [47] Kim, I.Y., Kang, Y.S., Lee, D.S., Park, H.J., Choi, E.K., Oh, Y.K., Son, H.J., Kim, J.S., Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release 140:1 (2009), 55–60.
48. [48] Swift, L.P., Rephaeli, A., Nudelman, A., Phillips, D.R., Cutts, S.M., Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 66:9 (2006), 4863–4871.
49. [49] Kim, K.R., Lee, Y.D., Lee, T., Kim, B.S., Kim, S., Ahn, D.R., Sentinel lymph node imaging by a fluorescently labeled DNA tetrahedron. Biomaterials 34:21 (2013), 5226–5235.
50. [50] Schroeder, A., Heller, D.A., Winslow, M.M., Dahlman, J.E., Pratt, G.W., Langer, R., Jacks, T., Anderson, D.G., Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12:1 (2012), 39–50.
51. [51] Wang, H., Li, B., Zhang, P., Yao, Y., Chang, J., Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumour Biol. 35:1 (2014), 595–601.
52. [52] Gomes, M., Teixeira, A.L., Coelho, A., Araujo, A., Medeiros, R., The role of inflammation in lung cancer. Adv. Exp. Med. Biol. 816 (2014), 1–23.
53. [53] Xu, L., Stevens, J., Hilton, M.B., Seaman, S., Conrads, T.P., Veenstra, T.D., Logsdon, D., Morris, H., Swing, D.A., Patel, N.L., Kalen, J., Haines, D.C., Zudaire, E., St Croix, B., COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med., 6(242), 2014, 242ra84.
54. [54] Li, M., Tang, Z., Zhang, D., Sun, H., Liu, H., Zhang, Y., Zhang, Y., Chen, X., Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models. Biomaterials 51 (2015), 161–172.
55. [55] MacDonald, N., Terminology in cancer cachexia: Importance and status. Curr. Opin. Clin. Nutr. Metab. Care 15:3 (2012), 220–225.
56. [56] Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J., Cancer-related inflammation and treatment effectiveness. Lancet Onco. 15:11 (2014), e493–e503.